Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA’s New Compliance Chief Donald Ashley Brings International Law Enforcement Experience

Executive Summary

Ashley's many years in the Department of Justice’s Office of International Affairs should be a plus for agency's globalization efforts.


Related Content

FDA GMP Warning Letters Review: Rate Soared In 2016 On Sterility And Data Integrity Concerns
US FDA Compliance Strategy: Meetings Replace Some Untitled Letters
US FDA Promises Shorter, Quicker Drug GMP Warning Letters
After Recusal, Schnedar Leaving CDER Compliance Office
FDA Inspections Ombudsman Could Help Foreign Manufacturers
Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US
House Demands More Info On FDA Overseas Operations
CDER Compliance Office Director Must Recuse Herself From Most Duties





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts